The nature and duration of treatment for gad

Acta Psychiatrica Scandinavica

Volumn 98, Issue SUPPL.S393, 1998, Pages 72-90

  Lader, M H ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Chronicity; Generalized anxiety disorder; Long term treatment

Indexed keywords

EID: 84882626326     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1002/9781444395211.ch5     Document Type: Article

References (78)

1. American Psychiatric Association. Diagnostic criteria from DSM-IV. Washington, DC: American Psychiatric Associ-ation. 1994.
2. World Health Organization. The ICD-10 classification of mental and behavioural disorders. Geneva: World Health Organization, 1992.
3. NAFIOLOWITZ D, DONOVAN S, FRANCIS A. DSM-IV. Impli-cations for drug therapy. CNS Drugs 1995: 4: 1-7.
4. WEISSMAN MM. Panic and generalized anxiety: are they sep-arate disorders? J Psychiatr Res 1990: 24: 157 162.
5. NOYES R, WOODMAN C, GARVEY MJ et al. Generalized anxiety disorder vs. panic disorder. J Nerv Ment Dis 1992: 180: 369-379.
6. MARKS J, LADER M. Anxiety states (anxiety neurosis): a review. J Nerv Ment Dis 1973: 156: 3-18.
7. REICH J. The epidemiology of anxiety. J Nerv Ment Dis 1986: 174: 129-136.
8. WEISSMAN MM, MYERS JK, HARDING PS. Psychiatric dis-orders in a US urban community: 1975-1976. Am J Psy-chiatry 1978: 135:459 462.
9. DEAN C, SURTEES PG, SASHIDHARAN SP. Comparison of re-search diagnostic systems in an Edinburgh community sample. Br J Psychiatry 1983: 142: 247 256.
10. UHLENHUTH EH, BALTER MB, MELLINGER GD et al. Symp-tom checklist syndromes in the general population. Arch Gen Psychiatry 1983: 40: 1167 1173.
11. WEISSMAN MM, MERIKANGAS KR. The epidemiology of anxiety and panic disorders: an update. J Clin Psychiatry 1986:47: 11-16.
12. KESSLER RC, MCGONAGLE KA, ZHAO S et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994: 51: 8-19.
13. ANGST J, VOLLRATH M. The natural history of anxiety dis-orders. Acta Psychiatr Scand 1991: 84: 446-452.
14. FILER SK, MATHIAS SD, PATRICK DL, MAZONSON PD, LU-BECK DP, BUESCHING DP. Untreated anxiety among adult primary care patients in a health maintenance organiza-tion. Arch Gen Psychiatry 1994: 51: 740-750.
15. ALLGULANDER C, LAVORI PW. Excess mortality among 3302 patients with 'pure' anxiety neurosis. Arch Gen Psy-chiatry 1991: 48: 599 602.
16. LADER M. Benzodiazepines. A risk-benefit profile. CNS Drugs 1994: 1: 377-387.
17. LADER M. Benzodiazepines the opium of the masses? Ne-uroscience 1978: 3: 159-165.
18. PETURSSON H, LADER M. Dependence on tranquillizers. Maudsley Monograph No. 28. Oxford: Oxford University Press, 1984.
19. KING DJ GRIFFITHS K, REILY PM. MERRETT JD. Psycho-tropic drug use in Northern Ireland 1966-80: prescribing trends, inter-and intra-regional comparisons and relation-ship to demographic and socio-economic variables. Psychol Med 1982: 12: 819-833.
20. SCHORR RI, ROBIN DW. Rational use of benzodiazepines in the elderly. Drugs Aging 1994: 4: 9-20.
21. BALTHR MB, MANHEIMER DI, MELLINGER GD. UHLENHUTH EH. A cross-national comparison of anti-anxiety/sedative drug use. Curr Med Res Opin 1984: 8 (Suppl. 4): 5-18.
22. BALTER MB. UHLENHUTH EH. Prescribing and use of benzodiazepines: an epidemiologic perspective. Psychoact Drugs 1992: 24: 63-64.
23. MELLINGER GD, BALTER MB, UHLENHUTH EH. Prevalence and correlates of the long-term regular use of anxiolytics. JAMA 1984: 251: 375-379.
24. CATALAN J, GATH DH, BOND A, EDMONDS G, MARTIN R ENNIS J. General practice patients on long-term psycho-tropic drugs. A controlled investigation. Br J Psychiatry 1988: 152: 399-105.
25. DUNHAR GC, PHRHRA MH, JHNNER FA. Patterns of benzodi-azepine use in Great Britain as measured by a general population survey. Br J Psychiatry 1989: 155: 836-841.
26. ASIITON H, GOLDING JF. Tranquillisers: prevalence, predic-tors and possible consequences. Data from a large United Kingdom survey. Br J Addict 1989: 84: 541-546.
27. DEANS HG, SKINNER P. Doctors' views on anxiety manage-ment in general practice. J R Soc Med 1992: 85: 83 86.
28. CLINTHORNE JK, CISIN IH, BALTER MB, MELLINGER GD, UHLENHUTH EH. Changes in popular attitudes and beliefs about tranquillizers. Arch Gen Psychiatry 1986: 43: 527-532.
29. BALTER MB, BAN TA, UHLENHUTH EH. International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications. I. Current con-cerns. Hum Psychopharmacology 1993: 8: 253-261.
30. GROF P. Designing long-term clinical trials in affective dis-orders. J Affect Disord 1994: 30: 243-255.
31. RICKETS K CASE G, DOWNING RW, WINOKUR A. Long-term diazepam therapy and clinical outcome. JAMA 1983: 250: 767-771.
32. RICKELS K, CASE GW, WINOKUR A, SWENSON C. Long-term benzodiazepine therapy: benefits and risks. Psychopharma-col Bull 1984: 20: 608 615.
33. RICKELS K, CASE G, DOWNING TW, FRIDMAN R. One-year follow-up of anxious patients treated with diazepam. J Clin Psychopharmacology 1986: 6: 32-35.
34. RICKELS K, CASE WG, DOWNING RW, WINOKUR A. Indi-cations and contraindications for chronic anxiolytic treat-ment: is there tolerance to the anxiolytic effect? In: KEMALI D, RACAGNI G, ed. Chronic treatments in neuropsychiatry. New York: Raven Press, 1985: 193-204.
35. RICKELS K, SCTIWEIZER E, CSANALOSI I, CASE WG, CHUNG H. Long-term treatment of anxiety and risk of withdrawal. Arch Gen Psychiatry 1988: 45: 444-450.
36. RICKELS K, CASE WG, SCHWEIZER E, GARCIA-ESPANA F FRIDMAN R. Long-term benzodiazepine users 3 years after participation in a discontinuation program. Am J Psy-chiatry 1991: 148: 757-761.
37. LUCKI I, RICKELS K, GELLER AM. Chronic use of benzodi-azepines and psychomotor and cognitive test performance. Psychopharmacology 1986: 88: 426-433.
38. GORENSTEIN C, BERNIK MA, POMI'EIA S. Differential acute psychomotor and cognitive effects of diazepam on long-term benzodiazepine users. Int Clin Psychopharmacology 1994: 9: 145-153.
39. UHLENHUTH EH, DE WIT H, BALTER MB, JOHANSON CE, MELLINGER GD. Risks and benefits of long-term benzodi-azepine use. J Clin Psychopharmacology 1988: 8: 161-167.
40. MARKS J. Chronic anxiolytic treatment: benefit and risk. In: KEMALI D, RACAGNI G, ed. Chronic treatments in neuropsychiatry. New York: Raven Press, 1985: 173-183.
41. NAGY A. Long-term treatment with benzodiazepines: the-oretical, ideological and practical aspects. Acta Psychiatr Stand 1987: 76 (suppl. 335): 47 55.
42. LYONS JS, LARSON DB, HROMCO J. Clinical and economic evaluation of benzodiazepines. A value analysis. Pharmac-oeconomics 1992: 2: 397 407.
43. ASHTON H. Guidelines for the rational use of benzodiaze-pines. When and what to use. Drugs 1994: 48: 25--0.
44. BALLHNGER JC, MCDONALD S, NOYES R et al. The first double-blind, placebo-controlled trial of a partial benzodi-azepine agonist, abecarnil (ZK 112-119), in generalized anxiety disorder. Psychopharmacol Bull 1991: 27: 171-179.
45. SPENCER CM, BENEIELD P. Abecarnil in generalized anxiety disorder: an initial appraisal of its clinical potential. CNS Drugs 1995: 3: 69 82.
46. POTOKAR J, Nurr DJ. Anxiolytic potential of benzodiaze-pine receptor partial agonists. CNS Drugs 1994: 1: 305-315.
47. SIEGHART W. Subpopulations of benzodiazepine receptors: implications for the pharmacology of inverse agonists. In: SARTER M. NUTT D, LISTER RG, ed. Benzodiazepine recep-tor inverse agonists. New York: Wiley-Liss, 1995: 1-24.
48. SCHWEIZER E, RICKLLS K. Pharmacological alternatives to benzodiazepine therapy of anxiety disorders. In: COSTA E SILVA JA, NADELSON CC, ed. International Review of Psy-chiatry. Vol. 1. Washington, DC: American Psychiatric Press, 1993: 267-281.
49. NEWTON RE, MARUNYCZ JD, ALDERDICE MT. Review of the side-effect profile of buspirone. Am J Med 1993: 80: 17-21.
50. O'HANLON JE Review of buspirone's effects on human per-formance and related variables. Neuropsychopharmacolo-gy 1991: 1:489-501.
51. ROBINSON DS, RICKELS K, FEIGHNER J et al. Clinical effects of the 5-HT, A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacology 1990: 10: 67S-73S.
52. DEAKIN JFW A review of clinical efficacy of 5-HT/A agonists in anxiety and depression. J Psychopharmacology 1993: 7: 283-289.
53. KENNETT GA. Mechanisms of serotonergic affect control. In: SCHWARTZ WT et al. ed. Kynurenine and serotonin pathways. New York: Plenum Press 1991: 231-243.
54. CUTLER NR SRAMEK JJ, WARDLE TS, KURTZ NM, KASH-KIN KB, HELLER A. Double-blind, placebo-controlled, par-allel-group comparison study of the efficacy and safety of ipsapirone and lorazepam in outpatients with generalized anxiety disorder. In: RACAGNI G, BRUNELLO N, FUKUDA T, ed. Biological psychiatry. Vol. 2. Amsterdam: Excerpta Medica, 1991: 901-904.
55. GLITZ DA, Pom, R. 5-HT, A partial agonists. What is their future. Drugs 1991: 41: 11-18.
56. LADER M. New psychopharmacological strategies for treat-ment of anxiety disorders. In: COSTA E SILVA JA, NADELSON CC, ed. International Review of Psychiatry. Vol. 1. Wash-ington, DC: American Psychiatric Press, 1993: 263-302.
57. HAMON M. Neuropharmacology of anxiety: perspectives and prospects. Trends Pharmacol Sci 1994: 15: 36-39.
58. TYRER P. Antidepressants in the treatment of anxiety dis-order. Psychiatr Bull 1993: 17: 75 76.
59. RAJ BA, SHEEHAN DV. Somatic treatment strategies in panic disorder. In: ASNIS GM, VAN PRAAG HM, ed. Panic disorder. Clinical, biological and treatment aspects. New York: Wiley, 1995: 279-313.
60. KAHN RJ, MCNAIR DM, LIPMAN RS et al. Imipramine and chlordiazepoxide in depressive and anxiety disorders. II. Ef-ficacy in anxious outpatients. Arch Gen Psychiatry 1986: 43: 79 85.
61. RICKELS K, DOWNING R, SCHWEIZER E, HASSMAN H. Anti-depressants for the treatment of generalized anxiety dis-order. Arch Gen Psychiatry 1993: 50: 884-895.
62. KAHN RJ, MCNAIR DM, FRANKENTHALER LM. Tricyclic treatment of generalized anxiety disorder. J Affect Disord 1987: 13: 145-151.
63. JOHNS TONE EC, CUNNINGHAM OWENS DG, FRITH CD et al. Neurotic illness and its response to anxiolytic and antide-pressant treatment. Psychol Med 1980: 10: 321-328.
64. HOEHN-SARIC R. Mcleod DR. Simmerli WD. Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J Clin Psy-chiatry 1988: 49: 293 301.
65. LAUX G, VOLZ H-P, MOLLER H-J. Newer and older mono-amine oxidase inhibitors. A comparative profile. CNS Drugs 1995: 3: 145-158.
66. LADER M. (5-adrenoceptor antagonists in neuropsychiatry: an update. J Clin Psychiatry 1988: 49: 213-223.
67. MORGAN J, TYRER P. Treating the somatic symptoms of anxiety. CNS Drugs 1994: 1: 427 434.
68. HAYES PE, SCHULZ SC. Beta-blockers in anxiety disorders. J Affect Disord 1987: 13: 119-130.
69. BUTLER G, CULLINGTON A, HIBBERT G. KLIMES I. GELDER M. Anxiety management for persistent generalised anxiety. Br J Psychiatry 1987: 151: 535-542.
70. BUTLER G, GELDER M, HIBBERT G, CULLINGTON A, KLIMES I. Anxiety management: developing effective strategies. Be-hav Res Ther 1987: 25: 517-522.
71. BECK AT, LAUDE R, BOHNERT M. Ideational components of anxiety neurosis. Arch Gen Psychiatry 1974: 31: 319-325.
72. DURHAM RC, ALLAN T Psychological treatment of general-ised anxiety disorder. A review of the clinical significance of results in outcome studies since 1980. Br J Psychiatry 1993: 163: 19-26.
73. KING MB. Counselling services in general practice. Psychi-atr Bull 1994: 18: 65-67.
74. DONNAN R HUTCHINSON A, PAXTON R, GRANT B, FIRTH M. Self-help materials for anxiety: a randomized controlled trial in general practice. Br J Gen Pract 1990: 40: 498-501.
75. CATALAN J, GATH D, EDMONDS G, ENNIS J. The effects of non-prescribing of anxiolytics in general practice. I. Con-trolled evaluation of psychiatric and social outcome. Br J Psychiatry 1984: 144: 593-602.
76. TYRER P, SEIVEWRIGHT N, MURPHY S et al. The Nottingham study of neurotic disorder: comparison of drug and psycho-logical treatments. Lancet 1988: ii: 235-240.
77. POWER KG, SIMPSON RJ, SWANSON V, WALLACE LA. FEISTNER ATC, SHARP D. A controlled comparison of cog-nitive behaviour therapy, diazepam, and placebo, alone and in combination, for the treatment of generalised anxiety disorder. J Anxiety Disord 1990: 4: 267 292.
78. LINDSAY WR, GAMSU CV, MCLAUGHLIN E, HOOD EM, Es-PIE CA. A controlled trial of treatments for generalized anxiety. Br J Clin Psychology 1987: 26: 3 15.